RPAY · Repay Holdings Corporation · Stock research

Current Thesis

The special situation that looked dead in late June has re-fired. Forager Capital Management submitted a revised all-cash proposal at $5.25 per share on 2026-06-29 — a 9% raise over the $4.80 the board rejected on 2026-05-04, and the second bid it has put on the table after losing every procedural round of the spring. The board rejected it unanimously on 2026-07-13, again calling it a significant undervaluation, with J.P. Morgan advising and Troutman Pepper Locke plus Sullivan & Cromwell on the legal side. On the same day it expanded from six to seven directors and seated Zachary F. Sadek, a senior partner at Parthenon Capital Partners — whose affiliate PCP Managers L.P. is one of the largest holders — under a new cooperation agreement. That is the tell on board intent: a friendly sponsor block formalized into a board seat one day after a raised bid. The stock re-rated off the June lows near $3.20 to a July high of $4.35, then faded to $3.88 by 2026-07-17. What an investor is buying here is not a payments growth story; it is a ~26% discount to a live cash bid from a 12.4% holder whose price has moved up, not down, through three months of rejection.

Bullish and bearish views on Repay Holdings Corporation

The model's bull view on Repay Holdings Corporation (RPAY), in brief: The bid ladder is going the right way. $4.80 (rejected 2026-05-04) → $5.25 (submitted 2026-06-29, rejected 2026-07-13). An activist that raises after losing a proxy vote is signalling committed capital, not a headline trade. The $5.25 level marks a 91% premium to the $2.75… The bear view: The board has now said no twice and hardened its register. Both cases follow in full.

Bull Case

• The bid ladder is going the right way. $4.80 (rejected 2026-05-04) → $5.25 (submitted 2026-06-29, rejected 2026-07-13). An activist that raises after losing a proxy vote is signalling committed capital, not a headline trade. The $5.25 level marks a 91% premium to the $2.75 30-day VWAP that prevailed when the original proposal landed.

• The 2026-06-10 vote is unresolved leverage. All six directors kept their seats under plurality voting, but on a ~36-37% withhold — the bottom ~1% of 17,000-plus Russell 3000 director elections in the 2025-2026 season. Boards carrying that number into a second cycle have a thin defense.
• The discount to the standing bid is wide. At $3.88 against a $5.25 proposal, the market prices roughly a one-in-four chance of a deal. DA Davidson's Peter Heckmann kept a Buy and a $6.00 target through the rejection; the five-analyst average sits near $6.85 versus a $342M market cap.
• Scale is genuinely larger post-KUBRA. The 2026-06-01 close adds ~$150-154M of revenue and ~$27.5-30M of adjusted EBITDA over the back seven months, taking reach past 40% of U.S. and Canadian households and ~$130B in combined annual payment volume. FY26 is guided to $490-500M revenue and $168.5-176M adjusted EBITDA.

Bear Case

• The board has now said no twice and hardened its register. Rejecting $5.25 while adding a sponsor-affiliated director under a cooperation agreement is a defense being built, not a process being run. Management language points at integrating KUBRA and "executing on its strategic plan," which is the vocabulary of staying independent.
• Leverage rewrote the buyout math in June. KUBRA was funded with a ~$600M Silver Point-led package — a $500M senior secured term loan plus a $100M undrawn revolver — putting gross leverage near 3x against ~$172M of guided EBITDA. A financial buyer now has to underwrite an already-levered balance sheet rather than the asset-light target Forager pitched in April.
• The underlying business is not growing. TTM revenue of $312.73M is up ~1%, organic growth is guided at only 10-12%, and the FY26 jump to $490-500M is KUBRA consolidation, not demand. TTM net income of -$258.72M (-$3.08 EPS) reflects impairment, and UBS held Neutral with a $4.25 target on 2026-06-03.
• The tape is fading the escalation. The stock has given back roughly 11% from the $4.35 July high and closed -4.43% on 2026-07-17. Post-rejection drift lower is how a market retires deal odds.
• Deal-contingent targets are not standalone value. Strip the bid and the comparable is a sub-scale, 3x-levered bill-pay processor with mid-single-digit organic growth, which is a low-multiple asset — the June round-trip to $3.20 showed where that clears.

Setup & Price Structure

Price sits at $3.88 (2026-07-17) inside a 52-week range of $2.30 to $6.06 and a market cap of $341.78M. The June 5 low near $3.20 marked the post-annual-meeting capitulation; the revised-proposal news re-rated the name to $4.35 intraday in early July, and the 2026-07-13 rejection began the give-back. The live structure is a widening gap between a $5.25 cash proposal and a tape that will not hold $4.00 — the discount is the trade and also the warning. The $3.45 area is where the entire revised-bid move gets returned; below it the chart is back in the pre-escalation $3.20-3.45 base with no premium embedded. Above, $4.35 is the level a third raise or a tender would have to clear. Volume near 460k shares on the down day is unremarkable, so there is no visible distribution flush yet. Trend-following signals are noise here; the chart moves on 8-K headlines, and standard extension or moving-average rules should not be applied to this structure.

Catalyst Calendar (next 30 days)

• ~2026-08-11 (est.) — Q2 2026 results, the first KUBRA-consolidated quarter (Q2 2025 landed 2025-08-11). The binary is whether organic growth ex-KUBRA holds double digits and whether integration costs pressure the $168.5-176M FY26 EBITDA guide. Entering a special-situation position into an earnings print that is not the thesis is the wrong risk.
• Ongoing, undated — A third 13D filer. Two independent activists at ~21% invites a cascade; a new filer is the highest-value unscheduled event available.

Elapsed catalysts

• Ongoing, undated — Forager's response to the 2026-07-13 rejection. A 13D/A, a further raise, or a move toward a consent solicitation or tender directly to holders would each reprice the name; silence past ~30 days reads as the campaign cooling. (passed 27d ago)
• Ongoing, undated — Follow-through on the 2026-06-18 USDC-on-Stellar stablecoin proof-of-concept. The tape sold that announcement -6.2%; a named client or revenue attached to it would be the first evidence the pivot is more than a demo. (passed 52d ago)

What Would Change Our Mind

The read breaks on a weekly close below $3.45, which erases the re-rating that the $5.25 proposal produced and puts the stock back in its pre-escalation base with no deal premium priced. It also breaks on a process event rather than a price one: Forager converting its 13D to a passive 13G, publicly withdrawing the proposal, or letting a full quarter pass without escalation would confirm the board has outlasted the campaign. On the other side, the setup upgrades materially if Forager raises a third time, launches a tender or consent solicitation, or if a third activist files a 13D — any of those turns a ~26% discount into a process with a clock. A Q2 print in mid-August that shows KUBRA integration slipping or organic growth below the 10-12% guide would remove the fundamental floor that makes the activists' valuation argument credible in the first place.

Correlation Notes

This trades on its own event calendar, not on payments-sector beta. Correlation to FIS, FISV and GPN is weak while a bid is outstanding; the relevant comparison set is other sub-$500M-cap activist-targeted processors and the broader small-cap take-private tape, which is sensitive to credit spreads — a widening high-yield market makes a levered buyout of an already 3x-levered target harder to finance. The KUBRA-driven utility and government bill-pay exposure adds a slow, defensive revenue base uncorrelated to consumer discretionary volumes. Nothing in the stablecoin proof-of-concept currently justifies grouping this with crypto-payment names; the 2026-06-18 reaction showed the market declining to pay for that association.